Parvovirus B19 in pregnancy

Exam relevance: in 10 of 197 board exam reports · rank 66

Synonyms
fifth disease, slapped cheek
Specialty
Obstetrics · Pregnancy disorders
Images
Ultrasound 1
Exam relevance
10 of 197 reports · rank 66
In the app
1 flashcards · GynFuchs
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (1)
  2. Definition
  3. Occurrence & epidemiology
  4. Aetiopathogenesis
  5. Clinical features
  6. Diagnosis
  7. Keep learning in the app
  8. Further reading (selection)
  9. Cross-references

Images (1)

Parvovirus B19 in pregnancy – Ultrasound: Middle cerebral artery Doppler with a peak systolic velocity of 1.91 MoM — pointing to fetal anaemia (Photo: Yanase Y, Sirilert S, Jatavan P, Pomrop M, Phirom K, Tongsong T. (Journal of …Ultrasound
Middle cerebral artery Doppler with a peak systolic velocity of 1.91 MoM — pointing to fetal anaemia (Photo: Yanase Y, Sirilert S, Jatavan P, Pomrop M, Phirom K, Tongsong T. (Journal of …Image: Yanase Y, Sirilert S, Jatavan P, Pomrop M, Phirom K, Tongsong T. (Journal of clinical medicine, 2025) · CC BY 4.0 · Source · cropped

Definition

Pathogen and Clinical Presentation

  • In children, the disease is called: fifth disease, i.e., erythema infectiosum.
  • Typical in children: malar erythema, lacy exanthem.
  • What the virus attacks: erythroid progenitor cells.
  • The fetus is therefore at risk of: aplastic anaemia, hydrops fetalis.
  • Predominant in adults: arthralgia, flu-like course.
  • The child is contagious: before the exanthem appears.
  • Parvovirus B19 infection in pregnancy is a maternal infection with the agent of erythema infectiosum (fifth disease) that can be transmitted transplacentally to the fetus.

Occurrence & epidemiology

Epidemiology

  • At the start of pregnancy, 34–65% of pregnant women are not immune, depending on the population studied.

Aetiopathogenesis

Aetiology and pathogenesis

  • The virus is transmitted via respiratory secretions, hand-to-mouth contact, blood products and transplacentally.
  • Fetal tissues, including haematopoietic cells and myocardium, express the viral P antigen receptor, which mainly explains anaemia and hydrops.
  • The rate of transmission to the fetus is 17–33%.
  • The fetus is most at risk in the first and second trimesters; after 20 weeks of gestation the risk of hydrops is 1% or less.

Clinical features

Clinical features and complications

  • In immunocompetent adults, infection is usually asymptomatic or mild; maternal manifestations include erythema infectiosum, arthropathy, anaemia and thrombocytopenia.
  • Fetal consequences include anaemia, thrombocytopenia, myocarditis, effusions, non-immune hydrops and intrauterine death; however, most infected fetuses remain unaffected.

Diagnosis

Fetal Monitoring

  • The crucial measurement is: PSV in the middle cerebral artery (MCA).
  • What causes it to increase in anaemia: lower blood viscosity.
  • Threshold for a suspected diagnosis of severe anaemia: PSV increase above 1.5 MoM.
  • Other signs on ultrasound: ascites, effusions, skin & placental edema.
  • Maternal diagnosis is based on IgG and IgM antibodies; IgM is detectable from the end of the first week of infection.
  • Fetal infection is detected by PCR of amniotic fluid.
  • A middle cerebral artery peak systolic velocity above 1.5 MoM is highly suggestive of moderate to severe fetal anaemia.
  • Ultrasound signs of hydrops are ascites, skin oedema, pleural and pericardial effusions and placental oedema.

Keep learning in the app

In the GynFuchs app you can learn Parvovirus B19 in pregnancy with flashcards, exam questions and image tasks (colposcopy, ultrasound, CTG) – free, in your browser or as an app.

In the app: 1 flashcards on this topic

Open in browser  About GynFuchs →

Further reading (selection)

  1. J Pers Med 2024: Parvovirus B19 Infection and Pregnancy: Review of the Current Knowledge (PubMed Central)
  2. DocCheck Flexikon, Ringelröteln

Cross-references

Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.